15.2  0.44 (2.98%)		10-03 16:00
Open: 14.83 High: 15.21 Volume: 298,368		Pre. Close: 14.76 Low: 14.83 Market Cap: 5,379(M)

Short term
Mid term
Targets	6-month :	18.17	1-year :	21.23
Resists	First :	15.56	Second :	18.17
Pivot price	14.97
Supports	First :	14.68	Second :	14.14
MAs	MA(5) :	14.93	MA(20) :	15.05
	MA(100) :	13.57	MA(250) :	15.56
MACD	MACD :	0	Signal :	0.1
%K %D	K(14,3) :	51.5	D(3) :	51
RSI	RSI(14): 55.5
52-week	High :	21.69	Low :	10.44

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ BLCO ] has closed below upper band by 30.3%. Bollinger Bands are 27.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	15.23 - 15.29	15.29 - 15.33
Low:	14.68 - 14.75	14.75 - 14.81
Close:	15.09 - 15.2	15.2 - 15.29

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

Fri, 03 Oct 2025
Assessing Bausch + Lomb (NYSE:BLCO) Valuation as Goldman Sachs Brings New Spotlight to Ophthalmology Growth Prospects - simplywall.st

Wed, 01 Oct 2025
Goldman Sachs Initiates Coverage of Bausch + Lomb (BLCO) with Neutral Recommendation - Nasdaq

Wed, 01 Oct 2025
Goldman Sachs Initiates Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Announces Target Price $16 - 富途牛牛

Wed, 01 Oct 2025
Goldman Sachs initiates Bausch & Lomb stock with Neutral rating By Investing.com - Investing.com Nigeria

Mon, 29 Sep 2025
Bausch + Lomb to Announce Q3 2025 Results and Host Investor Day - TipRanks

Mon, 29 Sep 2025
Global Eye Health Leader Bausch + Lomb Announces Q3 Earnings Date and Strategic Investor Day Pipeline Review - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	354 (M)
Shares Float	42 (M)
Held by Insiders	88 (%)
Held by Institutions	11.2 (%)
Shares Short	3,220 (K)
Shares Short P.Month	3,700 (K)

EPS	-0.78
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	18.2
Profit Margin	-5.6 %
Operating Margin	0.8 %
Return on Assets (ttm)	0.4 %
Return on Equity (ttm)	-4.1 %
Qtrly Rev. Growth	5 %
Gross Profit (p.s.)	8.25
Sales Per Share	13.81
EBITDA (p.s.)	1.49
Qtrly Earnings Growth	0 %
Operating Cash Flow	186 (M)
Levered Free Cash Flow	58 (M)

PE Ratio	-19.49
PEG Ratio	0
Price to Book value	0.83
Price to Sales	1.09
Price to Cash Flow	28.91

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.